Company profile
Dianthus Therapeutics, Inc. /DE/
NASDAQ:DNTHBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Claseprubart | phase3 | — | 4 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06537999 | phase2 | active_not_recruiting | 2024-09-17 | 2026-12-01 | Dianthus Therapeutics | A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy |
| NCT06282159 | phase2 | active_not_recruiting | 2024-02-23 | 2025-07-28 | Dianthus Therapeutics | A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC) |
| NCT07647510 | phase3 | recruiting | 2026-06-29 | 2028-12-01 | Dianthus Therapeutics | A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE) |
| NCT06858579 | phase3 | recruiting | 2025-02-10 | 2028-12-31 | Dianthus Therapeutics | A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) |
FDA applications (0)
No records yet.